Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic

 
• By Mandy Jackson
  
Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Novartis and Amgen ended Phase II/III studies for BACE inhibitor CNP520. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D